BUSINESS

Teva Takeda to License 10 APIs/20 Products from Sawai as It Plans to Shutter In-House Plants

August 21, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Teva Takeda Pharma, a Japanese joint venture of Takeda Pharmaceutical and Teva Pharmaceuticals Industries, will license 10 APIs/20 products from Sawai Pharmaceutical, bracing for its upcoming closure of two plants that are currently manufacturing 31 APIs/61 products. The move is…

To read the full story

Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019

BUSINESS

FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…